Galapagos | Salgsomkostninger Og Administration



Selling And Administration Expenses Lave om Dato
argenx SE USD 285.94M 8.24M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Genmab DKK 1.25B 384M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
GRIFOLS EUR 269.48M 49.95M 2024-12
Hikma Pharmaceutical USD 280M 4M 2024-06
Incyte USD 326.71M 17.5M 2024-12
Merck EUR 1.41B 72M 2024-09
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
UCB EUR 533M 434M 2024-06
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Galapagos Salgsomkostninger Og Administration - Aktuelle værdier, historiske data, prognoser, statistik, diagrammer og økonomisk kalender - Mar 2025.